<DOC>
	<DOCNO>NCT01214343</DOCNO>
	<brief_summary>The purpose study evaluate efficacy sorafenib combination low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy patient advance hepatocellular carcinoma .</brief_summary>
	<brief_title>Comparing Efficacy Sorafenib Versus Sorafenib Combination With Low-dose FP Patients With Advanced HCC</brief_title>
	<detailed_description>Sorafenib Low-dose FP Group Sorafenib administer orally dose 400 mg ( 2 x 200 mg tablet ) twice daily ( bid ) 28 day . Cisplatin dose 20mg/m2 administered day 1 day8 , fluorouracil dose 330mg/m2 administer continuously day1-day5 , day8-day12 via implant catheter system . Sorafenib Group Sorafenib administer orally dose 400 mg ( 2 x 200 mg tablet ) twice daily ( bid ) 28 day . The treatment regimen continue radiographic symptomatic progression , development unacceptable toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . 20 Years old . 2 . Life expectancy least 12 week pretreatment evaluation . 3 . Advanced hepatocellular carcinoma histological evidence biopsy specimen , typical finding dynamic CT CT hepatic arteriography/arterioportography . 4 . Not suitable resection local ablation therapy transcatheter arterial chemoembolization . 5 . ECOG Performance status 0 1 . 6 . Cirrhotic status ChildPugh score ≤ 7 . 7 . Adequate bone marrow , liver renal function , assess follow laboratory requirement : Hemoglobin ≥8.5 g/dl Granulocytes≥1500/μL Platelet count ≥50,000 /μL PTINR ≤ 2.3 Total serum bilirubin ≤ 2 mg/dl AST ( SGOT ) ALT ( SGPT ) ≤ 6 × upper limit normal Serum creatinine ≤ 1.5 × upper limit normal Amylase ≤ 2 × upper limit normal 8 . Written Informed Consent must obtain . 1 . Previous malignancy ( except cervical carcinoma situ , adequate treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis T1 ] , early gastric cancer , malignancy curatively treat &gt; 3 year prior entry 2 . Renal failure 3 . Any heart disease follow Congestive heart failure define NYHA class III IV Active coronary artery disease ischemic heart disease cardiac infarction within 6 month prior screen Serious cardiac arrhythmia Serious hypertension 4 . Active clinically serious infection except HBV HCV 5 . Active chicken pox . 6 . Auditory disorder . 7 . Known history HIV infection . 8 . Known metastatic meningeal tumor . 9 . Extrahepatic tumor spread affect patient 's prognosis 10 . History seizure disorder . 11 . Clinically significant gastrointestinal bleeding within 4 week prior study entry . 12 . Embolization infarction transient ischemic disease , deep vein thrombosis , pulmonary embolization . 13 . Any history treatment follow : Treatment agent induces CYP3A4 Surgical procedure within 4 week prior start study drug History organ allograft 14 . Patients unable swallow oral medication . 15 . Gastrointestinal disease may affect absorption drug pharmacokinetics . 16 . Medication may affect absorption drug pharmacokinetics . 17 . Any disease disorder may affect evaluation study drug . 18 . Entry clinical trial within 4 week prior entry study . 19 . Pregnant breastfeeding patient . 20 . Known allergy investigational agent agent give association trial . 21 . Substance abuse , medical , psychological social condition , judgment investigator , likely interfere patient 's participation study evaluation stuy result . 22 . Any condition unstable could jeopardize safety patient compliance study , investigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>sorafenib</keyword>
	<keyword>Hepatic intraarterial infusion chemotherapy</keyword>
	<keyword>HAIC</keyword>
	<keyword>Low dose FP</keyword>
	<keyword>cisplatin</keyword>
	<keyword>fluorouracil</keyword>
</DOC>